CALL FOR ABSTRACTS

• Early Stage/Localized Disease/Ablative Therapies
  Keywords: Neoadjuvant/ Adjuvant therapies, Early Stage, Minimally Invasive Surgery, Stage I, Stage II, Stereotactic Body Radiation Therapy
• Global Health
  Keywords: Patterns of care, lower socioeconomic countries global health
• Health Services Research/Health Economics
  Keywords: Health Policy, Cost Effectiveness, Quality of Care, Healthcare Access, Qualitative Research, Real-World Data, Observational Cohort Studies, Disease Registries And Databases, Artificial Intelligence, Machine Learning
• Immuno-Biology and Novel Immunotherapeutics (Phase I and Translational)
  Keywords: Tumor Micro-environment, Bi-specific Ab, Vaccine Therapy, Cellular Therapy, Chimeric Antigen Receptors, Viroimmunotherapy, Cytokine Therapy, Translational Research, Check-Point Blockade Beyond PD-1/L1
• Immunotherapy (Phase II/III Trials)
  Keywords: Phase II and III Clinical Trials, Immune Checkpoint Inhibitors, Randomised Controlled Trials, Biomarkers
• Liquid Biopsy and Other Non-invasive Diagnostic Modalities
  Keywords: Circulating Tumor Cells, Circulating Tumor DNA, Cell Free DNA, Circulating Cell-Free Noncoding RNAs, Circulating Exosomes, Liquid Biopsy, pleural effusion assays, urine based testing
• Locally Advanced NSCLC
  Keywords: Chemoradiation, immunotherapy, surgical resection, tri-modality therapy,   neoadjuvant
• Management of lung cancer in the era of COVID 19
  Keywords: Impact on care, complications, risk factors, impact on diagnosis and treatment
• Mesothelioma, Thymoma and Other Thoracic Malignancies
  Keywords: Malignant Mesothelioma, Thymoma, Thymic Carcinoma, Thymic Epithelial Tumors, Oesophageal Cancer
• Multimodality Management of Advanced Lung Cancer
  Keywords: Stereotactic Body Radiotherapy, Local Ablative Therapy, metastectomy, oligo-progression
• Novel Therapeutics and Targeted Therapies
  Keywords: novel cytotoxics, phase I, pre-clinical, anti-body conjugates
• Nursing and Allied Health Professionals
  Keywords: Rehabilitation, Physiotherapy, Survivorship Care
• Palliative and Supportive Care
  Keywords: Palliative care, Decision-making, Decision Support Techniques, Ethics, Quality of Life, Integrative care
• Patient Advocacy (Information for submitters to patient advocacy track)
  Keywords: Survivorship, Advocacy, Community Outreach, Patient-driven Research, Advocacy Foundations, Patient Advocacy, Patient Reported Outcomes, Lung Cancer Stigma
• Predictive Tumor Based Assays/Biomarkers/Pathology
  Keywords: tumor microenvironment, IHC. FISH, NGS, tissue diagnostics, novel tumor
• Risk Reduction and Tobacco Control
  Keywords: Tobacco Control Policy, Tobacco Prevention Patient, Framework Convention on Tobacco Control, Smoking Cessation, Radon, Bio Mass, Environmental
• Screening and Early Detection
  Keywords: Screening, Early Detection, Low Dose Spiral CT Scan, Early Diagnosis, Exhaled Air, Pulmonary Nodule, GGO, Biomarkers For Early Detection, Risk Models, Nodule Evaluation, Artificial Intelligence For Early Detection, Radiomics
• Small Cell Lung Cancer/NET
  Keywords: Small Cell Lung Cancer, Neuroendocrine Tumours, Atypical Carcinoid
• Staging/Pulmonary Medicine
  Keywords: Staging, Tumor Size Characteristics, Node Characteristics, Metastatic Characteristics, IASLC Staging System
• Tumor Biology and Systems Biology – Basic and Translational Science
  Keywords: Tumor Biology, Mouse Models, Basic Science, Translational Science, Bioinformatics, Transcriptomics and other novel omics,

Regular Abstract
Definition: Original scientific research that summarizes work done and major research findings.

Required sections for abstract submission:

• Introduction
• Methods
• Results
• Conclusion

Clinical Trials in Progress (eligible for designation as e-poster only)
Definition: Ongoing trials that have not reached pre-specified endpoints for analysis.

Required sections:

• Introduction
• Methods

Optional sections:

• Results
• Conclusion

Case Report (eligible for designation as e-poster only)
Definition: Detailed report of symptoms, signs, diagnosis, treatment and follow up of an individual patient.

Required sections for abstract submission:

• Introduction
• Methods
• Results
• Conclusion

Late-Breaking Abstract (LBA) Submission
Definition: LBA designation will only be given to clinically relevant prospective studies in which data is not available at the time of abstract placeholder submission due to study timelines.

LBA designation is not a means for extending the regular abstract deadline. Any abstract that fails to meet LBA requirements will be designated as a regular abstract and rated based on the information available on the submission deadline.

Submission requirements: Authors of LBA must submit a place holder abstract through the abstract portal by April 9, 2021 (23:59 PST).

Required sections for place holder abstracts:

• Explanation of why the abstract qualifies as late-breaking (including the endpoints for which data will be provided and the date for which the abstract will be updated prior to the LBA final submission deadline on July 10, 2021).
• Introduction
• Methods, including endpoints measured
• Types of analysis and anticipated data reporting
• Results and conclusion will be submitted by July 10, 2021

Review: The Scientific Program Committee will review LBA abstract placeholder applications. Authors of approved LBAs will be notified and instructed on deadlines and the processes for submitting final data by July 10, 2021, the final LBA deadline. LBA abstracts not completed by the July 10, 2021 deadline will be automatically withdrawn and will not be considered for the meeting.

Encore Submission: An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the abstract. Submitters are required to list any previously presented abstracts in the introduction of the abstract.

Financial disclosure and affiliation information is required for the presenting author. For reference, here is a link to the disclosure form.

Publication: Authors must agree to allow publication of accepted abstract(s) in the Journal of Thoracic Oncology (JTO) and the conference website. Most abstracts will be published and released prior to the meeting, except for embargoed abstracts which will be posted on the day of presentation.

Education Awards
These awards are presented to individuals with high scoring abstracts who meet categorical eligibility criteria and who apply. Applications must be completed by the abstract and education award submission deadline April 9, 2021 (23:59 PST).

Independence of Educational Activities Policy 

• Employees of ACCME defined ineligible companies are prohibited from presenting educational content for Continuing Medical Education. Consequently, employees of ineligible companies are prohibited from giving presentations during accredited CME sessions (e.g., Presidential and plenary symposia, oral and mini oral abstract sessions, and invited educational sessions).

Plagiarism Policy

• Definition: Plagiarism encompasses all of following:1. Direct: intentionally submitting another person’s words or ideas verbatim as one’s own;
  2. Self-plagiarism: submitting work that has been previously published or presented;
  3. Mosaic plagiarism: stringing together portions of text from other sources; and
  4. Lack of attribution: failing to appropriately identify and cite sources for language or ideas that are incorporated.

For more information see: Das N, Panjabi M. Plagiarism: Why is it such a big issue for medical writers? Perspect Clin Res. 2011;2(2):67–71. doi:10.4103/2229-3485.80370 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121267/ 

• Screening: IASLC screens all abstracts using anti-plagiarism software. Abstracts identified as having high levels of plagiarized content will be evaluated by IASLC staff and appropriate actions taken.

• Penalties for plagiarism may include: Rejection of abstract, and/or author(s) banned from making presentations at IASLC conferences.

• Employees of ACCME defined ineligible companies are prohibited from presenting educational content for Continuing Medical Education.   Consequently, employees of ineligible companies are prohibited from giving presentations during accredited CME sessions (e.g., Presidential and plenary symposia, oral and mini oral abstract sessions, and invited educational sessions) .
• In situations where the presenting author is an employee of an ineligible company, the abstract will automatically be considered for an e-poster.
• Presenting authors must be registered for WCLC 2021 independent of an ineligible company, except for employees of ineligible companies, who are allowed to be registered by their employers.
• Presenting author must control all content. Ineligible companies may not influence scientific content by requiring the use of company slide decks or other materials. Scientific data generated by industry sponsored research is permissible.
• Content of educational activities must be well-balanced, evidence based and unbiased. Generic names should be used to the extent possible.

When will the abstract titles be published online?
Abstract titles will be released August 9, 2021.

When will the full abstracts be published online?
The full abstract bodies will be released August 18, 2021 @ 18:00 EST except for those abstracts included in the WCLC 2021 Press Program.

Does WCLC accept abstracts that have been submitted and presented to a previous Conference (ie, encore abstracts, trials in progress encore abstracts)?
An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the presentation. Submitters are required to list any previous presentations in the introduction section of the abstract.

Are case reports/case series considered for presentations?
Yes, we do allow the submission of case reports.

What is the withdraw deadline for regular submissions and late breaking submissions?
The presenting author registration deadline is July 30, 2021. Abstract presentations for a presenter not registered by this date will be withdrawn from the program.

For late-breaking abstracts, does the Conference only permit abstracts that report on Phase 3 [and higher] studies?
Only clinically relevant prospective studies in which data is not available at the time of abstract placeholder submission (April 9, 2021) due to study timelines will be granted late-breaking submission privileges. An abstract study does not need to be a Phase III clinical trial to be eligible for late-breaking data submission.

Could I send my manuscript to publish to a journal in my country before WCLC?
Submitters may submit their abstract to be published in a journal prior to the abstract being released in conjunction with WCLC, however, the Scientific Program Committee will be reviewing abstracts for novelty and impact on patient care, and a publication in a journal prior to the meeting may impact the scoring of the abstract.

Is industry allowed to be in lead or senior author positions on the author list for WCLC abstract submissions? Are there restrictions towards pharmaceutical/commercial authors on presenting abstracts at the meeting?
Yes, industry is permitted to be in the lead and senior author positions in the author list of an abstract. Industry/pharmaceutical/commercial authors are prohibited from presenting Presidential, Oral, and Mini Oral presentations. Industry/pharmaceutical/commercial authors are permitted to present e-poster presentations.

Would it be possible to submit an abstract without results and conclusion?
All Regular Abstracts, Clinical Trials in Progress Abstracts, and Case Report abstracts must be completed by the April 9, 2021 deadline. Any Regular Abstracts and Case Reports that are incomplete after the April 9, 2021 deadline will be automatically withdrawn and will not be considered for the meeting. Clinical Trials in Progress abstracts may be submitted and completed by the April 9, 2021 deadline without Results and Conclusions as those sections are optional for CTPS submissions. Late-breaking Abstract designation will only be given to clinically relevant prospective studies in which data is not available at the time of abstract placeholder (April 9, 2021) due to study timelines. To submit a late-breaking abstract, you must submit a placeholder abstract including all components of the abstract except for the Results and Conclusions by the April 9, 2021 deadline.

Is there a limit on the number of abstracts in which an author can be lead author?
There is no limit to the number of abstracts in which an author can be lead author. An individual may not give more than two oral presentations.

Is there any charge for the submission of abstracts, and if so, how much is it?
No, there is no charge to submit an abstract to WCLC.

Do I need to submit COI Disclosure for all authors?
No, you only need to submit COI Disclosures for the presenting author on an abstract. A COI Disclosure form is available here for reference.

For inquiries, please contact wclc2021-abstracts at icsevents.com. If your inquiry is regarding a particular draft or submission, please include the abstract ID in your email.